Opportunities for preventing esophageal adenocarcinoma

Cancer Prevention Research

Volumn 9, Issue 11, 2016, Pages 828-834

  Maret Ouda, John ^a   El Serag, Hashem B ^b,c   Lagergren, Jesper ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

BACTERIAL CLEARANCE; BARIATRIC SURGERY; BARRETT ESOPHAGUS; CANCER PREVENTION; CANCER PROGNOSIS; CANCER SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS (TOPIC); OBESITY; OVERALL SURVIVAL; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING CESSATION; SURVIVAL RATE; SYSTEMATIC REVIEW (TOPIC); WEIGHT REDUCTION; ADENOCARCINOMA; ESOPHAGUS TUMOR;

ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; HUMANS;

EID: 84994735133     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-16-0170     Document Type: Review

References (69)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:E359-86.
2. Lagergren J, Lagergren P. Recent developments in esophageal adenocarci-noma. CA Cancer J Clin 2013; 63:232-48.
3. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut 2015; 64: 381-7.
4. Raman R, Deorah S, McDowell BD, Abu Hejleh T, Lynch CF, Gupta A. Changing incidence of esophageal cancer among white women: analysis of SEER data (1992-2010). Contemp Oncol (Pozn) 2015; 19: 338-40.
5. Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, et al. Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. Cancer Epidemiol Biomarkers Prev 2014; 23:997-1006.
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917.
7. Rutegard M, Charonis K, Lu Y, Lagergren P, Lagergren J, Rouvelas I. Population-based esophageal cancer survival after resection without neoadjuvant therapy: an update. Surgery 2012; 152:903-10.
8. Cen P, Banki F, Cheng L, Khalil K, Du XL, Fallon M, et al. Changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States. Ann Surg Oncol 2012; 19: 1685-91.
9. Spechler SJ, Souza RF. Barrett's esophagus. N Engl J Med 2014; 371: 836-45.
10. Kerkhof M, van Dekken H, Steyerberg EW, Meijer GA, Mulder AH, de Bruine A, et al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007; 50:920-7.
11. Sangle NA, Taylor SL, Emond MJ, Depot M, Overholt BF, Bronner MP. Overdiagnosis of high-grade dysplasia in Barrett's esophagus: a multicenter, international study. Mod Pathol 2015; 28:758-65.
12. Oxford Centre for Evidence-based Medicine - Levels of Evidence 2009; Available from: http://www.cebm.net/.
13. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340:825-31.
14. Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Changes in prevalence, incidence and spontaneous loss of gastro-oesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study. Gut 2012; 61:1390-7.
15. Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2010; 32:1222-7.
16. Maret-Ouda J, Brusselaers N, Lagergren J. What is the most effective treatment for severe gastro-oesophageal reflux disease? BMJ 2015; 350: h3169.
17. Iwao T, Toyonaga A, Kuboyama S, Tanikawa K. Effects of omeprazole and lansoprazole on fasting and postprandial serum gastrin and serum pepsinogen A and C. Hepatogastroenterology 1995; 42:677-82.
18. Abdalla SI, Lao-Sirieix P, Novelli MR, Lovat LB, Sanderson IR, Fitzgerald RC. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res 2004; 10:4784-92.
19. Haigh CR, Attwood SE, Thompson DG, Jankowski JA, Kirton CM, Pritchard DM, et al. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003; 124: 615-25.
20. Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut 2014; 63: 1229-37.
21. Hvid-Jensen F, Pedersen L, Funch-Jensen P, Drewes AM. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther 2014; 39:984-91.
22. Aydin Y, Akin H. Letter: proton pump inhibitor usage still seems to reduce the risk of high-grade dysplasia and/or oesophageal adenocarcinoma in Barrett's oesophagus. Aliment Pharmacol Ther 2014; 40:859-60.
23. Maret-Ouda J, Konings P, Lagergren J, Brusselaers N. Antireflux surgery and risk of esophageal adenocarcinoma: a systematic review and meta-analysis. Ann Surg 2016; 263:251-7.
24. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569-78.
25. Turati F, Tramacere I, La Vecchia C, Negri E. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol 2013; 24:609-17.
26. Hoyo C, Cook MB, Kamangar F, Freedman ND, Whiteman DC, Bernstein L, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol 2012; 41:1706-18.
27. Singh S, Sharma AN, Murad MH, Buttar NS, El-Serag HB, Katzka DA, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and metaanalysis. Clin Gastroenterol Hepatol 2013; 11:1399-412e7.
28. Chandar AK, Iyer PG. Role of obesity in the pathogenesis and progression of barrett's esophagus. Gastroenterol Clin North Am 2015; 44:249-64.
29. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292:1724-37.
30. Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev 2014; 8:CD003641.
31. Scozzari G, Trapani R, Toppino M, Morino M. Esophagogastric cancer after bariatric surgery: systematic review of the literature. Surg Obes Relat Dis 2013; 9:133-42.
32. Maret-Ouda J, Tao W, Mattsson F, Brusselaers N, El-Serag HB, Lagergren J. Esophageal adenocarcinoma after obesity surgery in a population-based cohort study. Surg Obes Relat Dis. 2015 Sep 26. [Epub ahead of print].
33. Tramacere I, La Vecchia C, Negri E. Tobacco smoking and esophageal and gastric cardia adenocarcinoma: a meta-analysis. Epidemiology 2011; 22: 344-9.
34. Cook MB, Kamangar F, Whiteman DC, Freedman ND, Gammon MD, Bernstein L, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst 2010; 102:1344-53.
35. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1:1311-5.
36. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacterpylori infection-the Maastricht IV/ florence consensus report. Gut 2012; 61:646-64.
37. Parkin DM The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118:3030-44.
38. Peleteiro B, Bastos A, Ferro A, Lunet N. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci 2014; 59:1698-709.
39. Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest 2009; 119:2475-87.
40. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003; 326:737.
41. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007; 5:1413-7, 7 e1-2.
42. Xie FJ, Zhang YP, Zheng QQ, Jin HC, Wang FL, Chen M, et al. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol 2013; 19:6098-107.
43. Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastro-enterol 2010; 105:1007-13; quiz 6, 14.
44. Tan J, Wang Y, Sun X, Cui W, Ge J, Lin L. The effect of Helicobacter pylori eradication therapyonthe development of gastroesophageal reflux disease. Am J Med Sci 2015; 349:364-71.
45. Edgren G, Adami HO, Weiderpass E, Nyren O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut 2013; 62:1406-14.
46. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004; CD002978.
47. North American Menopause S. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012; 19:257-71.
48. Warren MP Hormone therapy for menopausal symptoms: putting benefits and risks into perspective. J Fam Pract 2010; 59:E1-7.
49. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95:s1-s66.
50. Lagergren K, Lagergren J, Brusselaers N. Hormone replacement therapy and oral contraceptives and risk of oesophageal adenocarcinoma: a systematic review and meta-analysis. Int J Cancer 2014; 135:2183-90.
51. Menon S, Nightingale P, Trudgill N. Is hormone replacement therapy in post-menopausal women associated with a reduced risk of oesophageal cancer? United European Gastroenterol J 2014; 2:374-82.
52. Vane JR Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232-5.
53. Botting RM Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J Physiol Pharmacol 2006; 57 Suppl 5:113-24.
54. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygen-ase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001; 96:990-6.
55. Taddei A, Fabbroni V, Pini A, Lucarini L, Ringressi MN, Fantappie O, et al. Cyclooxygenase-2 and inflammation mediators have a crucial role in reflux-related esophageal histological changes and Barrett's esophagus. Dig Dis Sci 2014; 59:949-57.
56. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118:487-96.
57. Liao LM, Vaughan TL, Corley DA, Cook MB, Casson AG, Kamangar F, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 2012; 142:442-52.e5; quiz e22-3.
58. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:31-41.
59. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 2009; 100:551-7.
60. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003; 9:10-9.
61. Singh S, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastro-enterol Hepatol 2013; 11:620-9.
62. Cholesterol Treatment Trialists C, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012; 7:e29849.
63. Thrift AP, Kendall BJ, Pandeya N, Whiteman DC. A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2013; 11:138-44e2.
64. Xie SH, Lagergren J. A model for predicting individuals absolute risk of esophageal adenocarcinoma: moving towards tailored screening and prevention. Int J Cancer 2016; 138:2813-9.
65. Lagergren J, Ye W, Bergstrom R, Nyren O. Utility of endoscopic screening for upper gastrointestinal adenocarcinoma. JAMA 2000; 284:961-2.
66. Xie SH, Lagergren J. The male predominance in esophageal adenocarci-noma. Clin Gastroenterol Hepatol 2016; 14:338-47.
67. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008; 168:237-49.
68. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011; 365:1375-83.
69. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011; 103:1049-57.